Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Sponsor
Bristol-Myers Squibb
Study ID
NCT06499298
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    As per product label, as prescribed by treating physician

Study Details

The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.

Key Dates

Start date
Dec 3, 2024
Status verified
May 2025
Primary completion
Apr 16, 2025
Completion
Apr 16, 2025

Study Design

Enrollment
64 participants (actual)

Arms

  • Arm: Participants receiving adjuvant nivolumab

Primary Outcome Measure

Participant disease-free survival (DFS) [ Time Frame: Up to 1 year ]

Related Studies